Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review

Stefano Ballestri, Elisa Romagnoli, Dimitriy Arioli, Valeria Coluccio, Alessandra Marrazzo, Afroditi Athanasiou, Maria Di Girolamo, Cinzia Cappi, Marco Marietta, Mariano Capitelli, Stefano Ballestri, Elisa Romagnoli, Dimitriy Arioli, Valeria Coluccio, Alessandra Marrazzo, Afroditi Athanasiou, Maria Di Girolamo, Cinzia Cappi, Marco Marietta, Mariano Capitelli

Abstract

Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent conditions with a significant healthcare burden, and represent the main indications for anticoagulation. Direct oral anticoagulants (DOACs) are the first choice treatment of AF/VTE, and have become the most prescribed class of anticoagulants globally, overtaking vitamin K antagonists (VKAs). Compared to VKAs, DOACs have a similar or better efficacy/safety profile, with reduced risk of intracerebral hemorrhage (ICH), while the risk of major bleeding and other bleeding harms may vary depending on the type of DOAC. We have critically reviewed available evidence from randomized controlled trials and observational studies regarding the risk of bleeding complications of DOACs compared to VKAs in patients with AF and VTE. Special patient populations (e.g., elderly, extreme body weights, chronic kidney disease) have specifically been addressed. Management of bleeding complications and possible resumption of anticoagulation, in particular after ICH and gastrointestinal bleeding, are also discussed. Finally, some suggestions are provided to choose the optimal DOAC to minimize adverse events according to individual patient characteristics and bleeding risk.

Keywords: Anticoagulation reversal; Apixaban; Dabigatran; Edoxaban; Hemorrhage; Non-vitamin K antagonist oral anticoagulants; Rivaroxaban; Stroke; Thrombosis and embolism; Warfarin.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Management of bleeding complications on DOACs. Adapted from [99]. DOACs direct oral anticoagulants, HRS hepatorenal syndrome, 4F-PCC four factor-prothrombin complex concentrate, MB major bleeding, RBC red blood cells
Fig. 2
Fig. 2
Choosing the more appropriate anticoagulant based on patient profile. AF atrial fibrillation, APS antiphospholipid syndrome, BMI body mass index, CKD chronic kidney disease, CTP Child–Turcotte–Pugh score, eGFR estimated glomerular filtration rate, GERD gastroesophageal reflux disease, GIB gastrointestinal bleeding, VKA vitamin K antagonist, VTE venous thromboembolism. *AF patients: reduced dose 2.5 mg twice daily if criteria satisfied (Table 1); VTE patients: no dose reduction. ^AF patients: reduced dose 15 mg once daily; VTE patients: per SmPc reduced dose 15 mg once daily only if risk of bleeding outweighs risk for recurrent DVT/PE. °In AF/VTE patients meeting dose reduction criteria (Table 1)

References

    1. Di Carlo A, Bellino L, Consoli D, et al. Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: the FAI Project. Europace. 2019;21:1468–1475. doi: 10.1093/europace/euz141.
    1. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373–498. doi: 10.1093/eurheartj/ehaa612.
    1. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23:1612–1676. doi: 10.1093/europace/euab065.
    1. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) Eur Heart J. 2020;41:543–603. doi: 10.1093/eurheartj/ehz405.
    1. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4:4693–4738. doi: 10.1182/bloodadvances.2020001830.
    1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151. doi: 10.1056/NEJMoa0905561.
    1. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891. doi: 10.1056/NEJMoa1009638.
    1. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992. doi: 10.1056/NEJMoa1107039.
    1. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104. doi: 10.1056/NEJMoa1310907.
    1. Ntaios G, Papavasileiou V, Makaritsis K, Vemmos K, Michel P, Lip GYH. Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 2017;48:2494–2503. doi: 10.1161/STROKEAHA.117.017549.
    1. van den Ham HA, Souverein PC, Klungel OH, et al. Major bleeding in users of direct oral anticoagulants in atrial fibrillation: a pooled analysis of results from multiple population-based cohort studies. Pharmacoepidemiol Drug Saf. 2021;30:1339–1352. doi: 10.1002/pds.5317.
    1. Marston XL, Wang R, Yeh YC, et al. Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: a real-world cohort study. Int J Cardiol. 2022;1(346):93–99. doi: 10.1016/j.ijcard.2021.11.008.
    1. López-López JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:j5058. doi: 10.1136/bmj.j5058.
    1. Fralick M, Colacci M, Schneeweiss S, Huybrechts KF, Lin KJ, Gagne JJ. Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study. Ann Intern Med. 2020;172:463–473. doi: 10.7326/M19-2522.
    1. Li G, Lip GYH, Holbrook A, et al. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Eur J Epidemiol. 2019;34:173–190. doi: 10.1007/s10654-018-0415-7.
    1. Zhang J, Wang X, Liu X, et al. Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis. Eur J Epidemiol. 2021;36:793–812. doi: 10.1007/s10654-021-00751-7.
    1. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–2352. doi: 10.1056/NEJMoa0906598.
    1. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–2510. doi: 10.1056/NEJMoa1007903.
    1. Büller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287–1297. doi: 10.1056/NEJMoa1113572.
    1. Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11:21. doi: 10.1186/1477-9560-11-21.
    1. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799–808. doi: 10.1056/NEJMoa1302507.
    1. Buller HR, Décousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406–1415. doi: 10.1056/NEJMoa1306638.
    1. Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015;350:h1857. doi: 10.1136/bmj.h1857.
    1. Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018;362:k2505. doi: 10.1136/bmj.k2505.
    1. Goldhaber SZ, Ageno W, Casella IB, et al. Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study. J Thromb Thrombolysis. 2022;53:399–409. doi: 10.1007/s11239-021-02463-x.
    1. Bounameaux H, Haas S, Farjat AE, et al. Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. Thromb Res. 2020;191:103–112. doi: 10.1016/j.thromres.2020.04.036.
    1. Haas S, Mantovani LG, Kreutz R, et al. Anticoagulant treatment for venous thromboembolism: a pooled analysis and additional results of the XALIA and XALIA-LEA noninterventional studies. Res Pract Thromb Haemost. 2021;5:426–438. doi: 10.1002/rth2.12489.
    1. Bertoletti L, Gusto G, Khachatryan A, et al. Effectiveness and safety of oral anticoagulants in the treatment of acute venous thromboembolism: a Nationwide Comparative Cohort Study in France. Thromb Haemost. 2022 doi: 10.1055/a-1731-3922.
    1. Weycker D, Li X, Wygant GD, et al. Effectiveness and safety of apixaban versus warfarin as outpatient treatment of venous thromboembolism in US clinical practice. Thromb Haemost. 2018;118:1951–1961. doi: 10.1055/s-0038-1673689.
    1. Dawwas GK, Smith SM, Dietrich E, Lo-Ciganic WH, Park H. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism. Am J Health Syst Pharm. 2020;77:188–195. doi: 10.1093/ajhp/zxz307.
    1. Guo JD, Hlavacek P, Rosenblatt L, et al. Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States Medicare populatioldon. Thromb Res. 2021;198:163–170. doi: 10.1016/j.thromres.2020.11.039.
    1. Giustozzi M, Franco L, Vedovati MC, Becattini C, Agnelli G. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. J Thromb Thrombolysis. 2019;48:439–453. doi: 10.1007/s11239-019-01878-x.
    1. Aryal MR, Gosain R, Donato A, et al. Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Adv. 2019;3:2381–2387. doi: 10.1182/bloodadvances.2019000572.
    1. Liu ZY, Zhang HX, Ma LY, et al. Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies. BMC Cardiovasc Disord. 2022;22:105. doi: 10.1186/s12872-022-02550-8.
    1. Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368:709–718. doi: 10.1056/NEJMoa1113697.
    1. Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376:1211–1222. doi: 10.1056/NEJMoa1700518.
    1. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699–708. doi: 10.1056/NEJMoa1207541.
    1. Wang KL, van Es N, Cameron C, Castellucci LA, Büller HR, Carrier M. Extended treatment of venous thromboembolism: a systematic review and network meta-analysis. Heart. 2019;105:545–552. doi: 10.1136/heartjnl-2018-313617.
    1. Khan F, Tritschler T, Kimpton M, et al. Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta-analysis. Ann Intern Med. 2021;174:1420–1429. doi: 10.7326/M21-1094.
    1. Halvorsen S, Storey RF, Rocca B, et al. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on thrombosis. Eur Heart J. 2017;38:1455–1462.
    1. Meschia JF. Predicting who will experience cerebral hemorrhage when anticoagulated. Mayo Clin Proc. 2020;95:2057–2059. doi: 10.1016/j.mayocp.2020.08.025.
    1. Lv M, Wu T, Jiang S, Chen W, Zhang J. Risk of intracranial hemorrhage caused by direct oral anticoagulants for stroke prevention in patients with atrial fibrillation (from a network meta-analysis of randomized controlled trials) Am J Cardiol. 2022;1(162):92–99. doi: 10.1016/j.amjcard.2021.09.011.
    1. Wu T, Lv C, Wu L, et al. Risk of intracranial hemorrhage with direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Neurol. 2022;269:664–675. doi: 10.1007/s00415-021-10448-2.
    1. Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: risk, prevention and management. World J Gastroenterol. 2017;23:1954–1963. doi: 10.3748/wjg.v23.i11.1954.
    1. Deitelzweig S, Keshishian A, Kang A, et al. Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients. Ther Adv Gastroenterol. 2021;14:1756284821997352. doi: 10.1177/1756284821997352.
    1. Noseworthy PA, Yao X, Abraham NS, et al. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest. 2016;150:1302–1312. doi: 10.1016/j.chest.2016.07.013.
    1. Abraham NS, Noseworthy PA, Yao X, et al. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology. 2017;152:1014–1022. doi: 10.1053/j.gastro.2016.12.018.
    1. Mazurek M, Lip GYH. Gastrointestinal bleeding and direct oral anticoagulants amongst pati ents with atrial fibrillation in the "Real World". Gastroenterology. 2017;152:932–934. doi: 10.1053/j.gastro.2017.02.027.
    1. Rutherford OW, Jonasson C, Ghanima W, et al. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2020;6:75–85. doi: 10.1093/ehjcvp/pvz086.
    1. Ingason AB, Hreinsson JP, Ágústsson AS, et al. Rivaroxaban is associated with higher rates of gastrointestinal bleeding than other direct oral anticoagulants: a Nationwide Propensity Score-weighted study. Ann Intern Med. 2021;174:1493–1502. doi: 10.7326/M21-1474.
    1. Lip GYH, Keshishian AV, Zhang Y, et al. Oral anticoagulants for nonvalvular atrial fibrillation in patients with high risk of gastrointestinal bleeding. JAMA Netw Open. 2021;4:e2120064. doi: 10.1001/jamanetworkopen.2021.20064.
    1. Gu ZC, Wei AH, Zhang C, et al. Risk of major gastrointestinal bleeding with new vs conventional oral anticoagulants: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020;18:792–799.e61. doi: 10.1016/j.cgh.2019.05.056.
    1. Grymonprez M, Steurbaut S, De Backer TL, et al. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis. Front Pharmacol. 2020;11:583311. doi: 10.3389/fphar.2020.583311.
    1. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of longterm anticoagulation therapy (RE-LY) trial. Circulation. 2013;127:634–640. doi: 10.1161/CIRCULATIONAHA.112.115386.
    1. Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. 2018;320:2221–2230. doi: 10.1001/jama.2018.17242.
    1. Komen J, Pottegård A, Hjemdahl P, et al. Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds. Heart. 2022;108:613–618. doi: 10.1136/heartjnl-2021-319332.
    1. Kato ET, Goto S, Giugliano RP. Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. Ageing Res Rev. 2019;49:115–124. doi: 10.1016/j.arr.2018.10.006.
    1. Malik AH, Yandrapalli S, Aronow WS, Panza JA, Cooper HA. Meta-analysis of direct-acting oral anticoagulants compared with warfarin in patients >75 years of age. Am J Cardiol. 2019;123:2051–2057. doi: 10.1016/j.amjcard.2019.02.060.
    1. Ray WA, Chung CP, Stein CM, et al. Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation. JAMA. 2021;326:2395–2404. doi: 10.1001/jama.2021.21222.
    1. Richter D, Guasti L, Walker D, et al. Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Association for Acute Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, WG Thrombosis, of the European Society of Cardiology, European Primary Care Cardiology Society (EPCCS) Eur J Prev Cardiol. 2022;29:216–227. doi: 10.1093/eurjpc/zwaa167.
    1. He L, He R, Huang J, Zou C, Fan Y. Impact of frailty on all-cause mortality and major bleeding in patients with atrial fibrillation: a meta-analysis. Ageing Res Rev. 2022;73:101527. doi: 10.1016/j.arr.2021.101527.
    1. Wilkinson C, Wu J, Searle SD, et al. Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial. BMC Med. 2020;18:401. doi: 10.1186/s12916-020-01870-w.
    1. Kim DH, Pawar A, Gagne JJ, et al. Frailty and clinical outcomes of direct oral anticoagulants versus warfarin in older adults with atrial fibrillation: a cohort study. Ann Intern Med. 2021;174:1214–1223. doi: 10.7326/M20-7141.
    1. Steffel J, Giugliano RP, Braunwald E, et al. Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis. J Am Coll Cardiol. 2016;68:1169–1178. doi: 10.1016/j.jacc.2016.06.034.
    1. Rao MP, Vinereanu D, Wojdyla DM, et al. Clinical outcomes and history of fall in patients with atrial fibrillation treated with oral anticoagulation: insights from the ARISTOTLE trial. Am J Med. 2018;131:269–75e2. doi: 10.1016/j.amjmed.2017.10.036.
    1. Giugliano RP. Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation. Eur Heart J Suppl. 2022;24:A1–A10. doi: 10.1093/eurheartj/suab150.
    1. Gross PL, Chan NC. Thromboembolism in older adults. Front Med. 2021;7:470016. doi: 10.3389/fmed.2020.470016.
    1. Zhou B, Wu H, Wang C, Lou B, She J. Impact of age, sex, and renal function on the efficacy and safety of direct oral anticoagulants vs. vitamin k antagonists for the treatment of acute venous thromboembolism: a meta-analysis of 22,040 patients. Front Cardiovasc Med. 2021;8:700740. doi: 10.3389/fcvm.2021.700740.
    1. López-Núñez JJ, Pérez-Andrés R, Di Micco P, et al. Direct oral anticoagulants or standard anticoagulant therapy in fragile patients with venous thromboembolism. TH Open. 2019;3:e67–e76. doi: 10.1055/s-0039-1683970.
    1. Wang SY, Giugliano RP. Non-vitamin K antagonist oral anticoagulant for atrial fibrillation in obese patients. Am J Cardiol. 2020;127:176–183. doi: 10.1016/j.amjcard.2020.04.016.
    1. Boriani G, Ruff CT, Kuder JF, et al. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2019;40:1541–1550. doi: 10.1093/eurheartj/ehy861.
    1. Hohnloser SH, Fudim M, Alexander JH, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight. Circulation. 2019;139:2292–2300. doi: 10.1161/CIRCULATIONAHA.118.037955.
    1. Boriani G, Ruff CT, Kuder JF, et al. Edoxaban versus warfarin in patients with atrial fibrillation at the extremes of body weight: an analysis from the ENGAGE AF-TIMI 48 trial. Thromb Haemost. 2021;121:140–149. doi: 10.1055/s-0040-1716540.
    1. Martin AC, Thomas W, Mahir Z, et al. Direct oral anticoagulant concentrations in obese and high body weight patients: a cohort study. Thromb Haemost. 2021;121:224–233. doi: 10.1055/s-0040-1715834.
    1. Costa OS, Beyer-Westendorf J, Ashton V, et al. Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. Curr Med Res Opin. 2020;36:1081–1088. doi: 10.1080/03007995.2020.1762554.
    1. Berger JS, Laliberté F, Kharat A, et al. Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population. Curr Med Res Opin. 2021;37:881–890. doi: 10.1080/03007995.2021.1901223.
    1. Deitelzweig S, Keshishian A, Kang A, et al. Effectiveness and safety of oral anticoagulants among nvaf patients with obesity: insights from the ARISTOPHANES study. J Clin Med. 2020;9:1633. doi: 10.3390/jcm9061633.
    1. Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on control of anticoagulation. J Thromb Haemost. 2021;19:1874–1882. doi: 10.1111/jth.15358.
    1. Cohen AT, Pan S, Byon W, Ilyas BS, Taylor T, Lee TC. Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Adv Ther. 2021;38:3003–3018. doi: 10.1007/s12325-021-01716-8.
    1. Crouch A, Ng TH, Kelley D, et al. Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity. Pharmacotherapy. 2022;42:119–133. doi: 10.1002/phar.2655.
    1. Pandey AK, Eikelboom JW. Direct oral anticoagulant dosing in extremes of body weight: time to revisit the guidelines? Thromb Haemost. 2021;121:118–120. doi: 10.1055/s-0040-1716753.
    1. Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AFTIMI 48 trial. Lancet. 2015;385:2288–2295. doi: 10.1016/S0140-6736(14)61943-7.
    1. Covert K, Branam DL. Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations. Am J Health Syst Pharm. 2020;77:865–876. doi: 10.1093/ajhp/zxaa059.
    1. McCaughan GJB, Favaloro EJ, Pasalic L, Curnow J. Anticoagulation at the extremes of body weight: choices and dosing. Expert Rev Hematol. 2018;11:817–828. doi: 10.1080/17474086.2018.1517040.
    1. Chen A, Stecker E, Warden BA. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9:e017559. doi: 10.1161/JAHA.120.017559.
    1. Kreutz R, Camm AJ, Rossing P. Concomitant diabetes with atrial fibrillation and anticoagulation management considerations. Eur Heart J Suppl. 2020;22:O78–O86. doi: 10.1093/eurheartj/suaa182.
    1. Plitt A, Zelniker TA, Park JG, et al. Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58 634 patients across four randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2021;7:f40–f49. doi: 10.1093/ehjcvp/pvaa120.
    1. Cao B, Yao X, Zhang L, et al. Efficacy and safety of direct oral anticoagulants in patients with diabetes and nonvalvular atrial fibrillation: meta-analysis of observational studies. Cardiovasc Ther. 2021;2021:5520027. doi: 10.1155/2021/5520027.
    1. Huang HK, Liu PP, Lin SM, et al. Diabetes-related complications and mortality in patients with atrial fibrillation receiving different oral anticoagulants: a nationwide analysis. Ann Intern Med. 2022;175:490–498. doi: 10.7326/M21-3498.
    1. Kumar S, Lim E, Covic A, et al. Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week. J Am Coll Cardiol. 2019;74:2204–2215. doi: 10.1016/j.jacc.2019.08.1031.
    1. Weitz JI, Prandoni P, Verhamme P. Anticoagulation for patients with venous thromboembolism: when is extended treatment required? TH Open. 2020;4:e446–e456. doi: 10.1055/s-0040-1721735.
    1. Catella J, Bertoletti L, Mismetti P, et al. Severe renal impairment and risk of bleeding during anticoagulation for venous thromboembolism. J Thromb Haemost. 2020;18:1728–1737. doi: 10.1111/jth.14837.
    1. Ando G, Capranzano P. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: a systematic review and network meta-analysis. Int J Cardiol. 2017;231:162–169. doi: 10.1016/j.ijcard.2016.11.303.
    1. Cheung CYS, Parikh J, Farrell A, Lefebvre M, Summa-Sorgini C, Battistella M. Direct oral anticoagulant use in chronic kidney disease and dialysis patients with venous thromboembolism: a systematic review of thrombosis and bleeding outcomes. Ann Pharmacother. 2021;55:711–722. doi: 10.1177/1060028020967635.
    1. González Pérez A, Balabanova Y, Sáez ME, Brobert G, García Rodríguez LA. Renal decline in patients with non-valvular atrial fibrillation treated with rivaroxaban or warfarin: a population-based study from the United Kingdom. Int J Cardiol. 2022;S0167–5273:00190–195. doi: 10.1016/j.ijcard.2022.01.063.
    1. Sy J, Hsiung JT, Edgett D, Kalantar-Zadeh K, Streja E, Lau WL. Cardiovascular and bleeding outcomes with anticoagulants across kidney disease stages: analysis of a national US cohort. Am J Nephrol. 2021;52:199–208. doi: 10.1159/000514753.
    1. Chokesuwattanaskul R, Thongprayoon C, Tanawuttiwat T, Kaewput W, Pachariyanon P, Cheungpasitporn W. Comparative safety and efficacy of apixaban versus warfarin in patients with end stage renal disease: meta-analysis. Pacing Clin Electrophysiol. 2018;41:627–634. doi: 10.1111/pace.13331.
    1. Malhotra K, Ishfaq MF, Goyal N, et al. Oral anticoagulation in patients with chronic kidney disease: a systematic review and meta-analysis. Neurology. 2019;92:e2421–e2431. doi: 10.1212/WNL.0000000000007534.
    1. Ballestri S, Capitelli M, Fontana MC, et al. Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: a narrative review. Adv Ther. 2020;37:1910–1932. doi: 10.1007/s12325-020-01307-z.
    1. Violi F, Loffredo L, Pastori D. Anticoagulation in patients with advanced liver disease: an open issue. Intern Emerg Med. 2021;16:61–71. doi: 10.1007/s11739-020-02526-6.
    1. Serper M, Weinberg EM, Cohen JB, Reese PP, Taddei TH, Kaplan DE. Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation. Hepatology. 2021;73:219–232. doi: 10.1002/hep.31264.
    1. Menichelli D, Ronca V, Di Rocco A, Pignatelli P, Podda GM, CAR Direct oral anticoagulants and advanced liver disease: a systematic review and meta-analysis. Eur J Clin Invest. 2021;51:e13397. doi: 10.1111/eci.13397.
    1. Violi F, Vestri A, Menichelli D, Di Rocco A, Pastori D, Pignatelli P. Direct oral anticoagulants in patients with atrial fibrillation and advanced liver disease: an exploratory meta-analysis. Hepatol Commun. 2020;4:1034–1040. doi: 10.1002/hep4.1513.
    1. Marietta M, Coluccio V, Luppi M. COVID-19, coagulopathy and venous thromboembolism: more questions than answers. Intern Emerg Med. 2020;15:1375–1387. doi: 10.1007/s11739-020-02432-x.
    1. Giannis D, Douketis JD, Spyropoulos AC. Anticoagulant therapy for COVID-19: what we have learned and what are the unanswered questions? Eur J Intern Med. 2022;96:13–16. doi: 10.1016/j.ejim.2021.11.003.
    1. Marietta M, Ageno W, Artoni A, et al. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET) Blood Transfus. 2020;18:167–169.
    1. Al-Samkari H, Connors JM. Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. Blood Adv. 2019;3:3770–3779. doi: 10.1182/bloodadvances.2019000369.
    1. Cosmi B. An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis. Expert Opin Pharmacother. 2021;22:583–594. doi: 10.1080/14656566.2020.1847273.
    1. Yun JP, Choi EK, Han KD, et al. Risk of atrial fibrillation according to cancer type: a nationwide population-based study. JACC CardioOncol. 2021;3:221–232. doi: 10.1016/j.jaccao.2021.03.006.
    1. Davis MK, Lim H, Lee AYY. Direct oral anticoagulants in patients with cancer and nonvalvular atrial fibrillation. JACC CardioOncol. 2021;3:425–427. doi: 10.1016/j.jaccao.2021.07.003.
    1. Mariani MV, Magnocavallo M, Straito M, et al. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis. J Thromb Thrombolysis. 2021;51:419–429. doi: 10.1007/s11239-020-02304-3.
    1. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315–352. doi: 10.1016/j.chest.2015.11.026.
    1. Ageno W, Donadini M. Breadth of complications of long-term oral anticoagulant care. Hematol Am Soc Hematol Educ Progr. 2018;2018:432–438. doi: 10.1182/asheducation-2018.1.432.
    1. Clemens A, Strack A, Noack H, et al. Anticoagulant-related gastrointestinal bleeding—could this facilitate early detection of benign or malignant gastrointestinal lesions? Ann Med. 2014;46:672–678. doi: 10.3109/07853890.2014.952327.
    1. Flack KF, Desai J, Kolb JM, et al. Major gastrointestinal bleeding often is caused by occult malignancy in patients receiving warfarin or dabigatran to prevent stroke and systemic embolism from atrial fibrillation. Clin Gastroenterol Hepatol. 2017;15:682–690. doi: 10.1016/j.cgh.2016.10.011.
    1. Raposeiras Roubín S, Abu Assi E, Barreiro Pardal C, et al. New cancer diagnosis after bleeding in anticoagulated patients with atrial fibrillation. J Am Heart Assoc. 2020;9:e016836. doi: 10.1161/JAHA.120.016836.
    1. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91–99. doi: 10.1016/S0002-9343(98)00198-3.
    1. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF) Am Heart J. 2006;151:713–719. doi: 10.1016/j.ahj.2005.04.017.
    1. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol. 2011;58:395–401. doi: 10.1016/j.jacc.2011.03.031.
    1. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–1100. doi: 10.1378/chest.10-0134.
    1. O'Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015;36:3258–3264.
    1. Hijazi Z, Oldgren J, Lindbäck J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016;387:2302–2311. doi: 10.1016/S0140-6736(16)00741-8.
    1. Barnett-Griness O, Stein N, Kotler A, Saliba W, Gronich N. Novel bleeding prediction model in atrial fibrillation patients on new oral anticoagulants. Heart. 2022;108:266–273. doi: 10.1136/heartjnl-2021-319702.
    1. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood. 1991;78:2337–2343. doi: 10.1182/blood.V78.9.2337.2337.
    1. Kuijer PM, Hutten BA, Prins MH, Büller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999;159:457–460. doi: 10.1001/archinte.159.5.457.
    1. Ruíz-Giménez N, Suárez C, González R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100:26–31. doi: 10.1160/TH08-03-0193.
    1. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e419S–e496S. doi: 10.1378/chest.11-2301.
    1. Klok FA, Hösel V, Clemens A, et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J. 2016;48:1369–1376. doi: 10.1183/13993003.00280-2016.
    1. Klok FA, Huisman MV. How I assess and manage the risk of bleeding in patients treated for venous thromboembolism. Blood. 2020;135:724–734. doi: 10.1182/blood.2019001605.
    1. Marques Antunes M, Alves M, Pinto FJ, Agnelli G, Caldeira D. The high-risk bleeding category of different scores in patients with venous thromboembolism: systematic review and meta-analysis. Eur J Intern Med. 2021;94:45–55. doi: 10.1016/j.ejim.2021.10.014.
    1. Hellenbart EL, Faulkenberg KD, Finks SW. Evaluation of bleeding in patients receiving direct oral anticoagulants. Vasc Health Risk Manag. 2017;13:325–342. doi: 10.2147/VHRM.S121661.
    1. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76:594–622. doi: 10.1016/j.jacc.2020.04.053.
    1. Hemphill JC, III, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46:2032–2060. doi: 10.1161/STR.0000000000000069.
    1. Dionne JC, Oczkowski SJW, Hunt BJ, et al. Tranexamic acid in gastrointestinal bleeding: a systematic review and meta-analysis. Crit Care Med. 2022;50:e313–e319. doi: 10.1097/01.ccm.0000808652.67085.74.
    1. King B, Milling T, Gajewski B, et al. Restarting and timing of oral anticoagulation after traumatic intracranial hemorrhage: a review and summary of ongoing and planned prospective randomized clinical trials. Trauma Surg Acute Care Open. 2020;5:e000605. doi: 10.1136/tsaco-2020-000605.
    1. Nielsen PB, Skjøth F, Søgaard M, et al. Non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with intracerebral hemorrhage. Stroke. 2019;50(4):939–946. doi: 10.1161/STROKEAHA.118.023797.
    1. Poli D, Antonucci E, Vignini E, et al. Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs. Eur J Intern Med. 2020;80:73–77. doi: 10.1016/j.ejim.2020.05.020.
    1. Botto GL, Ameri P, De Caterina R. Many good reasons to switch from vitamin K antagonists to non-vitamin K antagonists in patients with non-valvular atrial fibrillation. J Clin Med. 2021;10:2866. doi: 10.3390/jcm10132866.
    1. Hawkes MA, Rabinstein AA. Anticoagulation for atrial fibrillation after intracranial hemorrhage: a systematic review. Neurol Clin Pract. 2018;8:48–57. doi: 10.1212/CPJ.0000000000000425.
    1. Piran S, Schulman S. Treatment of bleeding complications in patients on anticoagulant therapy. Blood. 2019;133:425–435. doi: 10.1182/blood-2018-06-820746.
    1. Steiner T, Al-Shahi Salman R, Beer R, et al. European stroke organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke. 2014;9:840–855. doi: 10.1111/ijs.12309.
    1. Wiegele M, Schöchl H, Haushofer A, et al. Diagnostic and therapeutic approach in adult patients with traumatic brain injury receiving oral anticoagulant therapy: an Austrian interdisciplinary consensus statement. Crit Care. 2019;23:62. doi: 10.1186/s13054-019-2352-6.
    1. Chai-Adisaksopha C, Hillis C, Monreal M, Witt DM, Crowther M. Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. a meta-analysis. Thromb Haemost. 2015;114:819–825. doi: 10.1160/TH15-01-0063.
    1. Tapaskar N, Pang A, Werner DA, Sengupta N. Resuming anticoagulation following hospitalization for gastrointestinal bleeding is associated with reduced thromboembolic events and improved mortality: results from a systematic review and meta-analysis. Dig Dis Sci. 2021;66:554–566. doi: 10.1007/s10620-020-06248-9.
    1. Witt DM. What to do after the bleed: resuming anticoagulation after major bleeding. Hematol Am Soc Hematol Educ Progr. 2016;2016:620–624. doi: 10.1182/asheducation-2016.1.620.
    1. Scott MJ, Veitch A, Thachil J. Reintroduction of anti-thrombotic therapy after a gastrointestinal haemorrhage: if and when? Br J Haematol. 2017;177:185–197. doi: 10.1111/bjh.14599.
    1. Candeloro M, van Es N, Cantor N, et al. Recurrent bleeding and thrombotic events after resumption of oral anticoagulants following gastrointestinal bleeding: communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost. 2021;19:2618–2628. doi: 10.1111/jth.15476.
    1. Lip GYH, Lane DA. Matching the NOAC to the patient: remember the modifiable bleeding risk factors. J Am Coll Cardiol. 2015;66:2282–2284. doi: 10.1016/j.jacc.2015.07.086.
    1. Schaefer JK, McBane RD, Wysokinski WE. How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. Ann Hematol. 2016;95:437–449. doi: 10.1007/s00277-015-2566-x.
    1. Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J. 2017;38:860–868.
    1. Geldhof V, Vandenbriele C, Verhamme P, Vanassche T. Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants. Thromb J. 2014;13(12):21. doi: 10.1186/1477-9560-12-21.
    1. Huisman MV, Ferreira M, Feuring M, Fraessdorf M, Klok FA. Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism. J Thromb Haemost. 2018;16:1775–1778. doi: 10.1111/jth.14226.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe